Ceftazidime/avibactam (CAZ-AVI) is a promising novel agent with activity against carbapenem-resistant Enterobacteriaceae (CRE). Here, we describe the dynamic evolution of a KPC-producing Klebsiella pneumoniae (KPC-Kp) infection in a critically ill patient treated with CAZ-AVI-tigecycline combination therapy.
Suboptimal drug exposure leads selection of different subpopulations of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae in a critically ill patient / Gaibani, Paolo; Gatti, Milo; Rinaldi, Matteo; Crovara, Cristina; Lazzarotto, Tiziana; Giannella, Maddalena; Lombardo, Donatella; Amadesi, Stefano; Viale, Pierluigi; Pea, Federico; Ambretti, Simone. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - ELETTRONICO. - 113:(2021), pp. 213-217. [10.1016/j.ijid.2021.10.028]
Suboptimal drug exposure leads selection of different subpopulations of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae in a critically ill patient
Gaibani, Paolo;Gatti, Milo;Rinaldi, Matteo;Lazzarotto, Tiziana;Giannella, Maddalena;Lombardo, Donatella;Viale, Pierluigi;Pea, Federico;Ambretti, Simone
2021
Abstract
Ceftazidime/avibactam (CAZ-AVI) is a promising novel agent with activity against carbapenem-resistant Enterobacteriaceae (CRE). Here, we describe the dynamic evolution of a KPC-producing Klebsiella pneumoniae (KPC-Kp) infection in a critically ill patient treated with CAZ-AVI-tigecycline combination therapy.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S120197122100816X-main.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
491.58 kB
Formato
Adobe PDF
|
491.58 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
